Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

linical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)...  VA North Texas Health Care System announces ... a technology-based, scientifically advanced weight loss therapy.  ... the Maestro® Rechargeable System that intermittently blocks intra-abdominal ... food intake and processing between the brain and ... to meet the needs of a patient,s changing ...
(Date:6/3/2015)... , June 3, 2015 aTyr Pharma, Inc. (NASDAQ: ... and development of Physiocrine-based therapeutics to address rare diseases, today ... William Blair Growth Stock Conference to be held at the ... June 9-11, 2015. John Mendlein , aTyr,s ... on the Company at 9:20 a.m. CT on Wednesday, June ...
(Date:6/3/2015)... 2015  Armetheon, Inc., a specialty pharmaceutical company ... today announced that Sanjay Kakkar , MD, ... effective immediately. Dr. Kakkar brings more than 20 ... a successful track record in advancing novel technologies ... that includes the development of novel drugs and ...
Breaking Medicine Technology:VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4
... Patient Record Sharing , and Secure ... Among Physicians , DAYTON, Ohio, Oct. 29 ... (HSI) announce an effort to create virtual teams that connect primary ... care of patients, improving the quality and safety of care while ...
... IRVINE, Calif., Oct. 29 PRO-DEX, INC. (Nasdaq: PDEX ... quarter ending September 30, 2009. In addition, Pro-Dex announced ... renewed, a new marketing director has been hired, a product ... shipments have been made of a newly developed product. , ...
Cached Medicine Technology:Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 2Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 3Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10
(Date:6/3/2015)... (PRWEB) June 03, 2015 Acne is the ... can be particularly stubborn to eliminate and hard to prevent. ... common in teens and young adults, in the years when ... sebum, or oil,” says Jayme Bashian, director and lead medical ... pimples, blackheads and cysts of acne are caused by oil ...
(Date:6/3/2015)... 2015 First Choice Emergency Room ... in the United States, announced that it is opening ... June. , “I am pleased to announce that ... new facility in the San Antonio area,” said Dr. ... Emergency Room. , First Choice Emergency Room is ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Come on ... Relay , a 200-mile overnight relay beginning in Madison, ... Illinois on Saturday, June 13th. , For the 4th ... the Brainstormers will run to raise money for the ... of different members of the Neurosurgery staff from The ...
(Date:6/2/2015)... 03, 2015 BALTIMORE, Md. – ... a book about wellness after being diagnosed with lupus. ... that through lifestyle changes which enhance health, lupus and ... “ A Wellspring for Wellness ,” she offers a ... , This book provides an overview of some autoimmune ...
(Date:6/2/2015)... Aidan Booth And Steve Clayton's ... yesterday, and has since received rave reviews from ... Tiffany Hendricks has weighed in with her opinion ... on her website HonestyFirstReviews.com. , "These days the ... looking to hone their business skills has gotten ...
Breaking Medicine News(10 mins):Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:First Choice Emergency Room to Open New Facility in San Antonio, Texas 2Health News:4th Annual Ragnar Relay from Madison, WI to Chicago, IL Once Again Benefits Renowned Brain Aneurysm Foundation 2Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2
... Medical Center has just enrolled the first U.S. patient in ... certain kinds of melanoma, a deadly skin cancer that in ... than blocking or killing all rapidly dividing cells, whether malignant ... new class of agents that have been designed to sabotage ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... 30 (HealthDay News) -- Early assessment of rheumatoid arthritis ... the likelihood of disease remission without having to take ... Although DMARDs are considered effective in treating rheumatoid ... been linked to uncommon but serious side effects. ...
... their employer, or through an employed family member,s dependent coverage. ... to a new policy brief from the UCLA Center for ... California Health Interview Survey (CHIS), the brief,s authors found that ... with at least one employed family member or 5.7 ...
... of more than 2 million mammogram screenings performed on nearly ... time show a direct link between reduced hormone therapy and ... invasive breast cancer. The researchers saw such a striking decrease, ... promote breast tumor growth. The declines occurred in ...
... system for Wilson,s disease (WD) provides good diagnostic accuracy ... in children with mild liver disease. In asymptomatic children, ... suggestive of WD, however the penicillamine challenge test (PCT) ... subset. Results of the study appear in the December ...
Cached Medicine News:Health News:International clinical trial tests targeted drug for melanoma 2Health News:Better Outcomes Seen With Early Rheumatoid Arthritis Diagnosis 2Health News:5.7 million Californians lack access to job-based coverage 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 3Health News:Scoring system is 93 percent accurate for diagnosing Wilson's disease in pediatric patients 2
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... simple, effective screening test which is used to ... levels which are often a warning sign of ... which requires a single drop of blood obtained ... shown in clinical trials to be 94 to ...
The Lifestream Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program. At a later date, you can purchase the other components...
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
Medicine Products: